BioCentury | Jun 15, 2015
Finance

Deerfield pays Tribute to Pozen

Deerfield is betting $300 million on the combination of a Canadian cardiovascular specialty pharma with a U.S. biotech that has new management, a late-stage cardio asset and a royalty stream. The firm is backing a...
BC Week In Review | Aug 11, 2014
Company News

Bial-Portela, moksha8 deal

Bial-Portela granted moksha8 an exclusive license to commercialize epilepsy treatment Zebinix eslicarbazepine acetate in Brazil and Mexico. The voltage-gated sodium and T-type calcium channel blocker is not yet approved in either country. moksha8 plans to...
BC Week In Review | Jul 28, 2014
Clinical News

Aptiom eslicarbazepine acetate regulatory update

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary said Health Canada approved Aptiom eslicarbazepine acetate as a once-daily adjunctive therapy to treat partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. The...
BC Week In Review | May 26, 2014
Clinical News

Zebinix eslicarbazepine acetate regulatory update

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said the Italian Medicines Agency (AIFA) approved the reimbursement of Zebinix eslicarbazepine as an adjunct treatment for partial-onset seizures in adult epileptics with or without secondary generalization. Earlier this...
BC Week In Review | Apr 14, 2014
Company News

Dainippon Sumitomo sales and marketing update

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary launched Aptiom eslicarbazepine acetate in the U.S. as an add-on therapy to treat partial-onset seizures in adult epileptics. The wholesale acquisition cost (WAC) for a 30-count package of 400 or...
BC Week In Review | Feb 10, 2014
Clinical News

Zebinix eslicarbazepine acetate regulatory update

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said Finnish Health Authorities granted full reimbursement for Zebinix eslicarbazepine acetate for adjunctive therapy in adults with partial onset seizures, with or without secondary generalization. Eisai has marketing rights...
BC Week In Review | Jan 20, 2014
Clinical News

Aptiom eslicarbazepine acetate: Additional Phase III data

On the secondary endpoint of change from baseline in standardized seizure frequency during the 18-week, double-blind treatment period, eslicarbazepine led to a median reduction in seizure frequency of 30.9% in the 1,200 mg arm and...
BC Week In Review | Nov 11, 2013
Clinical News

Aptiom eslicarbazepine acetate regulatory update

FDA approved an NDA from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary for Aptiom eslicarbazepine as an add-on therapy to treat partial-onset seizures in adults with epilepsy. The company plans to launch the drug in the U.S....
BC Extra | Nov 9, 2013
Company News

FDA approves Dainippon's Aptiom for seizures

FDA approved an NDA from the Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506) for Aptiom eslicarbazepine (formerly Stedesa ) as an add-on therapy to treat partial-onset seizures in adults with epilepsy. The...
BC Week In Review | Nov 4, 2013
Clinical News

Zebinix eslicarbazepine acetate regulatory update

Dainippon disclosed in its earnings for the 6 months ended Sept. 30 that in June it submitted a regulatory application to Health Canada for eslicarbazepine as adjunctive therapy to treat epilepsy. The product is under...
Items per page:
1 - 10 of 718
BioCentury | Jun 15, 2015
Finance

Deerfield pays Tribute to Pozen

Deerfield is betting $300 million on the combination of a Canadian cardiovascular specialty pharma with a U.S. biotech that has new management, a late-stage cardio asset and a royalty stream. The firm is backing a...
BC Week In Review | Aug 11, 2014
Company News

Bial-Portela, moksha8 deal

Bial-Portela granted moksha8 an exclusive license to commercialize epilepsy treatment Zebinix eslicarbazepine acetate in Brazil and Mexico. The voltage-gated sodium and T-type calcium channel blocker is not yet approved in either country. moksha8 plans to...
BC Week In Review | Jul 28, 2014
Clinical News

Aptiom eslicarbazepine acetate regulatory update

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary said Health Canada approved Aptiom eslicarbazepine acetate as a once-daily adjunctive therapy to treat partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. The...
BC Week In Review | May 26, 2014
Clinical News

Zebinix eslicarbazepine acetate regulatory update

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said the Italian Medicines Agency (AIFA) approved the reimbursement of Zebinix eslicarbazepine as an adjunct treatment for partial-onset seizures in adult epileptics with or without secondary generalization. Earlier this...
BC Week In Review | Apr 14, 2014
Company News

Dainippon Sumitomo sales and marketing update

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary launched Aptiom eslicarbazepine acetate in the U.S. as an add-on therapy to treat partial-onset seizures in adult epileptics. The wholesale acquisition cost (WAC) for a 30-count package of 400 or...
BC Week In Review | Feb 10, 2014
Clinical News

Zebinix eslicarbazepine acetate regulatory update

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said Finnish Health Authorities granted full reimbursement for Zebinix eslicarbazepine acetate for adjunctive therapy in adults with partial onset seizures, with or without secondary generalization. Eisai has marketing rights...
BC Week In Review | Jan 20, 2014
Clinical News

Aptiom eslicarbazepine acetate: Additional Phase III data

On the secondary endpoint of change from baseline in standardized seizure frequency during the 18-week, double-blind treatment period, eslicarbazepine led to a median reduction in seizure frequency of 30.9% in the 1,200 mg arm and...
BC Week In Review | Nov 11, 2013
Clinical News

Aptiom eslicarbazepine acetate regulatory update

FDA approved an NDA from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary for Aptiom eslicarbazepine as an add-on therapy to treat partial-onset seizures in adults with epilepsy. The company plans to launch the drug in the U.S....
BC Extra | Nov 9, 2013
Company News

FDA approves Dainippon's Aptiom for seizures

FDA approved an NDA from the Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506) for Aptiom eslicarbazepine (formerly Stedesa ) as an add-on therapy to treat partial-onset seizures in adults with epilepsy. The...
BC Week In Review | Nov 4, 2013
Clinical News

Zebinix eslicarbazepine acetate regulatory update

Dainippon disclosed in its earnings for the 6 months ended Sept. 30 that in June it submitted a regulatory application to Health Canada for eslicarbazepine as adjunctive therapy to treat epilepsy. The product is under...
Items per page:
1 - 10 of 718